Amicus Therapeutics (NASDAQ:FOLD) Price Target Lowered to $17.00 at Wells Fargo & Company
Amicus Therapeutics (NASDAQ:FOLD – Free Report) had its price objective cut by Wells Fargo & Company from $18.00 to $17.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. A number of other equities analysts have also issued reports on FOLD. Needham & […]
Amicus Therapeutics (NASDAQ:FOLD – Free Report) had its price objective cut by Wells Fargo & Company from $18.00 to $17.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. A number of other equities analysts have also issued reports on FOLD. Needham & […]
